Dual PPAR α/γ Agonism Normalizes Lipoprotein Profile of Renal Dyslipidemia
Table 3
Plasma apolipoprotein concentrations levels (mg/dL) in patients with chronic renal insufficiency (n = 23) and healthy reference subjects (n = 17) at start and end of treatment with 1 mg tesaglitazar o.d. Mean, standard deviation, and 95% confidence interval (in parenthesis).
CKD patients
Healthy reference group
At entry
After 6 weeks
Estimated change
At entry
After 6 weeks
Estimated change
Apo A-I
141 (16)
153 (21)
+9%**
145 (23)
154 (20)
+7%
Apo B
126 (34)
104 (31)
−18%***
105 (16)
87 (17)
−17%***
Apo B/Apo A-I
0.9 (0.3)
0.7 (0.3)
−24%***
0.7 (0.2)
0.6 (0.1)
−22%***
Apo C-III
16.6 (5.4)
17.4 (3.9)
+6%
11.4 (2.4)
11.1 (2.5)
−3%
Apo C-III-HS
9.1 (2.3)
11.4 (3.8)
+30%***
8.3 (2.5)
8.1 (2.3)
+2%
Apo C-III-HP
6.8 (3.0)
5.7 (2.6)
−13%**
3.6 (1.0)
3.2 (1.2)
−14%**
Apo C-III ratio
1.5 (0.7)
2.5 (1.6)
+55%**
2.3 (0.9)
2.9 (1.6)
+19%
Apo A-I/Apo C-III
9.0 (2.0)
9.2 (2.0)
+9%
13.2 (2.7)
14.3 (2.5)
+2%
Apo E
7.8 (2.9)
8.2 (2.6)
+5%
5.5 (1.2)
6.0 (1.8)
+8%
P < 0.01 and ***P < 0.001 with group comparison between baseline and after 6 weeks of treatment.
